Relieving Eye Itch and Preventing Vision Loss in Demodex Blepharitis: Optimizing Diagnosis and Integration of Novel Treatment

Tracking # 20-1297765

Free

There are no ratings for this course

Educator MED LEARNING GROUP

CE Broker Reporting Reported automatically

Method Computer-Based Training

Course overview

This program is designed to help optometrists and ophthalmologists better identify the best methods for early detection and differentiation of Demodex blepharitis from other ocular conditions to facilitate a timely and accurate diagnosis; and assess the clinical profiles of approved novel therapeutic agents that promote mite eradication.

Subject areas

This course counts toward the state boards and subject areas below.

Florida Board of Medicine

Anesthesiologist Assistant

0.75h General (AMA Category I)

Area of Critical Need Medical Doctor

0.75h General (AMA Category I)

Medical Doctor

0.75h General (AMA Category I)

Medical Doctor Faculty Certificate

0.75h General (AMA Category I)

Medical Doctor Limited License

0.75h General (AMA Category I)

Medical Doctor Limited to Cleveland Clinic

0.75h General (AMA Category I)

Medical Doctor Limited to Mayo Clinic

0.75h General (AMA Category I)

Medical Doctor Public Health Certificate

0.75h General (AMA Category I)

Medical Doctor Public Psychiatry

0.75h General (AMA Category I)

Medical Doctor Visiting Faculty Certificate

0.75h General (AMA Category I)

Georgia Board of Nursing

Licensed Practical Nurse

0.75h General

Registered Professional Nurse

0.75h General

Georgia Composite Medical Board - Physician Assistants

Physician Assistant

0.75h Physician Assistant General CME

Georgia Composite Medical Board - Physicians & Telemedicine

Institutional Physician

0.75h General CME

Physician

0.75h General CME

Telemedicine

0.75h General CME

Kentucky Board of Nursing

Advanced Practice Registered Nurse

0.75h Continuing education related to pharmacology

Licensed Practical Nurse

0.75h Continuing education related to nursing

Registered Nurse

0.75h Continuing education related to nursing

Michigan Board of Dentistry

Dental Assistant

0.5h General

Dental Hygienist

0.5h General

Dental Therapist

0.5h General

Dentist

0.5h General

North Dakota Board of Nursing

Advanced Practice Registered Nurse

0.75h Pharmacotherapy Related to Scope of Practice

Licensed Practical Nurse

0.75h Social, Legal, and Ethical Aspects of Nursing Practice

Registered Nurse

0.75h Pharmacotherapy Related to Scope of Practice

Oklahoma Board of Dentistry

Dental Assistant

0.75h General CE

Dental Hygienist

0.75h General CE

Dentist

0.75h General CE

Oral Maxillofacial Surgery Assistant

0.75h General CE

Texas Medical Board - Physicians

Physician

0.75h Formal Category 1 or 1A Hours

Disclosure statements

Eric Donnenfeld, MD Has received consulting fees from AbbVie, Inc., Alcon, Aldeyra, Allegro, Aurion, Bausch + Lomb, BVI, BlephEx, CorneaGen, Covalent, Crystilex, CRST, ELT Sight, Katena, LacriPen, LayerBio, LensGen, Mati Pharmaceuticals, Melt Pharmaceuticals, MDBackline, Mynosis, Nanowafer, Nordic Pharma, Novaliq, OcuHub, Ocular Innovations, Ocular Therapeutix, Oculus, Omega Ophthalmics, Oyster Point Pharma, PRN, Rayner, ReTear, TearScience, Tenpoint, Théa, Trukera, Zeiss

Has stocks, stock options, or other ownership interest excluding diversified mutual funds in Allegro, Aurion, BlephEx, CorneaGen, Covalent, Crystilex, ELT Sight, LacriPen, LayerBio, LensGen, Mati Pharmaceuticals, Melt Pharmaceuticals, MDBackline, Mynosis, OcuHub, Ocular Innovations, Oculus, Omega Ophthalmics, PRN, Rayner, ReTear, Singular Strategies, Strathspey Crown, Surface, Tarsus Pharmaceuticals, Inc., Tenpoint, Versant Ventures, Visionary Ventures